Literature DB >> 27405064

Differential Expression of PCSK9 Modulates Infection, Inflammation, and Coagulation in a Murine Model of Sepsis.

Dhruva J Dwivedi1, Peter M Grin, Momina Khan, Annik Prat, Ji Zhou, Alison E Fox-Robichaud, Nabil G Seidah, Patricia C Liaw.   

Abstract

INTRODUCTION: Proprotein convertase subtilisin/kexin type 9 (PCSK9) targets lipoprotein receptors for degradation, thereby reducing hepatic lipid clearance. PCSK9 inhibition reduces mortality in septic mice, presumably through increased hepatic clearance of pathogen lipids due to increased lipoprotein receptor concentrations. However, PCSK9 overexpression in vivo has not been studied in sepsis. Therefore, this study aimed to evaluate the effects of differential PCSK9 expression on systemic infection, inflammation, and coagulation in sepsis.
METHODS: Wild-type, PCSK9 knockout (KO), and transgenic (Tg) mice that overexpress PCSK9 were subjected to sham surgery or cecal ligation and puncture (CLP). Bacterial loads were measured in lungs, peritoneal cavity fluid, and blood. Organ pathology was assessed in lungs, liver, and kidneys. Lung myeloperoxidase activity, and plasma concentrations of alanine aminotransferase (ALT), creatinine, cell-free DNA (cfDNA), protein C, thrombin-antithrombin (TAT) complexes, interleukin (IL)-6, and IL-10 were also measured 6 h postoperatively. Morbidity was assessed for 16 h following CLP.
RESULTS: Overexpression of PCSK9 in mice increased liver and kidney pathology, plasma IL-6, ALT, and TAT concentrations during sepsis, whereas PCSK9 KO mice exhibited reduced bacterial loads, lung and liver pathology, myeloperoxidase activity, plasma IL-10, and cfDNA during CLP-induced sepsis. All septic mice had reduced plasma levels of protein C, but the protein C ratio relative to normal was significantly decreased in PCSK9 Tg mice. Dyspnea, cyanosis, and overall grimace scores were greatest in septic mice overexpressing PCSK9, whereas PCSK9 KO mice retained core body temperature during sepsis.
CONCLUSION: These findings demonstrate that PCSK9 deficiency confers protection against systemic bacterial dissemination, organ pathology, and tissue inflammation, particularly in the lungs and liver, while PCSK9 overexpression exacerbates multi-organ pathology as well as the hypercoagulable and pro-inflammatory states in early sepsis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27405064     DOI: 10.1097/SHK.0000000000000682

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  45 in total

Review 1.  Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.

Authors:  Nabil G Seidah; Annik Prat; Angela Pirillo; Alberico Luigi Catapano; Giuseppe Danilo Norata
Journal:  Cardiovasc Res       Date:  2019-03-01       Impact factor: 10.787

Review 2.  Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology.

Authors:  José Tuñón; Lina Badimón; Marie-Luce Bochaton-Piallat; Bertrand Cariou; Mat J Daemen; Jesus Egido; Paul C Evans; Imo E Hoefer; Daniel F J Ketelhuth; Esther Lutgens; Christian M Matter; Claudia Monaco; Sabine Steffens; Erik Stroes; Cécile Vindis; Christian Weber; Magnus Bäck
Journal:  Cardiovasc Res       Date:  2019-01-01       Impact factor: 10.787

3.  Plasma PCSK9 levels and sepsis severity: an early assessment in the emergency department.

Authors:  Francesca Innocenti; Anna Maria Gori; Betti Giusti; Camilla Tozzi; Chiara Donnini; Federico Meo; Irene Giacomelli; Maria Luisa Ralli; Alice Sereni; Elena Sticchi; Irene Tassinari; Rossella Marcucci; Riccardo Pini
Journal:  Clin Exp Med       Date:  2020-08-31       Impact factor: 3.984

4.  Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome.

Authors:  Thomas S Metkus; Bo Soo Kim; Steven R Jones; Seth S Martin; Steven P Schulman; Thorsten M Leucker
Journal:  Front Med (Lausanne)       Date:  2022-06-13

Review 5.  The Understanding and Management of Organism Toxicity in Septic Shock.

Authors:  Kelly Roveran Genga; Tadanaga Shimada; John H Boyd; Keith R Walley; James A Russell
Journal:  J Innate Immun       Date:  2018-05-15       Impact factor: 7.349

6.  Inflammatory cytokine expression in patients with sepsis at an intensive care unit.

Authors:  Lili Wang; Hongyan Zhao; Dongxu Wang
Journal:  Exp Ther Med       Date:  2018-06-29       Impact factor: 2.447

7.  CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death.

Authors:  Yves Lévy; Aurélie Wiedemann; Boris P Hejblum; Mélany Durand; Cécile Lefebvre; Mathieu Surénaud; Christine Lacabaratz; Matthieu Perreau; Emile Foucat; Marie Déchenaud; Pascaline Tisserand; Fabiola Blengio; Benjamin Hivert; Marine Gauthier; Minerva Cervantes-Gonzalez; Delphine Bachelet; Cédric Laouénan; Lila Bouadma; Jean-François Timsit; Yazdan Yazdanpanah; Giuseppe Pantaleo; Hakim Hocini; Rodolphe Thiébaut
Journal:  iScience       Date:  2021-06-10

Review 8.  The Multifaceted Biology of PCSK9.

Authors:  Nabil G Seidah; Annik Prat
Journal:  Endocr Rev       Date:  2022-05-12       Impact factor: 25.261

Review 9.  PCSK9 Biology and Its Role in Atherothrombosis.

Authors:  Cristina Barale; Elena Melchionda; Alessandro Morotti; Isabella Russo
Journal:  Int J Mol Sci       Date:  2021-05-30       Impact factor: 5.923

Review 10.  Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis.

Authors:  Emily Punch; Justus Klein; Patrick Diaba-Nuhoho; Henning Morawietz; Mahdi Garelnabi
Journal:  J Am Heart Assoc       Date:  2022-01-20       Impact factor: 6.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.